Gynecology Service, Department of Surgery, and the Medical Library, Memorial Sloan Kettering Cancer Center, and the Joan & Sanford I. Weill Medical College of Cornell University, New York, New York; and the Department of Obstetrics and Gynecology, Danbury Hospital, Nuvance Health, Danbury, Connecticut.
Obstet Gynecol. 2020 Sep;136(3):533-542. doi: 10.1097/AOG.0000000000003952.
To assess surgical, oncologic, and pregnancy outcomes in patients undergoing radical vaginal, abdominal, or laparoscopic trachelectomy for the treatment of early-stage cervical cancer, using a methodic review of published literature.
PubMed, EMBASE, and Cochrane Library sources, including ClinicalTrials.gov, were searched from 1990-2019 with terms "cervical cancer" and "(vaginal, abdominal, open, minimally invasive, or laparoscopic) radical trachelectomy." Grey literature and unpublished data were omitted.
After removal of duplicates from a combined EndNote library of results, 490 articles were reviewed using Covidence software. Two reviewers screened titles and abstracts, and then screened full texts. Selection criteria included articles that reported radical trachelectomy with lymph node assessment as primary therapy for cervical carcinoma, with stated follow-up intervals and recurrences.
TABULATION, INTEGRATION, AND RESULTS: Variables of interest were manually extracted into an electronic database. A total 47 articles that reported on 2,566 women met inclusion criteria. Most tumors were of squamous histology (68.5%), stage IB1 (74.8%), 2 cm or less (69.2%), and without lymphovascular invasion (68.8%). Of planned trachelectomies, 9% were converted intraoperatively to hysterectomy. Separated by route of trachelectomy, 58.1%, 37.2%, and 4.7% were performed using radical vaginal, abdominal, and laparoscopic approaches, respectively. With median follow-up of 48 months (range 2-202 months) across studies, median recurrence rate was 3.3% (range 0-25%); median time to recurrence was 26 months (range 8-44 months). Median 5-year recurrence-free and overall survival were 94.6% (range 88-97.3%) and 97.4% (range 95-99%), respectively. The posttrachelectomy pregnancy rate was 23.9%, with a live-birth rate of 75.1%.
Radical trachelectomy for fertility-preserving treatment of cervical cancer is widely reported in the literature, though publications are mainly limited to case reports and case series. Reported follow-up periods infrequently meet standard oncologic parameters but show encouraging recurrence-free and overall survival rates and pregnancy outcomes. Higher-level evidence needed for meta-analysis is lacking.
PROSPERO, CRD42019132443.
通过对已发表文献的系统回顾,评估因早期宫颈癌行根治性阴道、腹部或腹腔镜子宫颈管切除术的患者的手术、肿瘤学和妊娠结局。
从 1990 年至 2019 年,通过使用术语“宫颈癌”和(阴道、腹部、开放式、微创或腹腔镜)根治性子宫颈管切除术,在 PubMed、EMBASE 和 Cochrane 图书馆来源(包括 ClinicalTrials.gov)中进行了搜索。排除了灰色文献和未发表的数据。
在对 EndNote 结果库进行合并后,从 490 篇文章中删除重复项,然后使用 Covidence 软件进行审查。两名审查员筛选标题和摘要,然后筛选全文。入选标准包括报道作为宫颈癌主要治疗方法行根治性子宫颈管切除术且有明确随访间隔和复发情况的文章。
列表、综合和结果:将感兴趣的变量手动提取到电子数据库中。共有 47 篇报道了 2566 名女性的文章符合纳入标准。大多数肿瘤为鳞状组织学(68.5%)、IB1 期(74.8%)、2cm 或以下(69.2%)和无淋巴血管侵犯(68.8%)。计划的子宫颈管切除术中有 9%在术中转为子宫切除术。根据子宫颈管切除术的途径,分别有 58.1%、37.2%和 4.7%采用根治性阴道、腹部和腹腔镜方法进行。在研究中,中位随访时间为 48 个月(范围 2-202 个月),中位复发率为 3.3%(范围 0-25%);中位复发时间为 26 个月(范围 8-44 个月)。中位 5 年无复发生存率和总生存率分别为 94.6%(范围 88-97.3%)和 97.4%(范围 95-99%)。子宫颈管切除术后妊娠率为 23.9%,活产率为 75.1%。
文献中广泛报道了根治性子宫颈管切除术用于保留生育力治疗宫颈癌,但出版物主要限于病例报告和病例系列。报告的随访期很少符合标准的肿瘤学参数,但显示出令人鼓舞的无复发生存率和总生存率以及妊娠结局。缺乏进行荟萃分析的更高水平证据。
PROSPERO,CRD42019132443。